Maxim Group reiterated their buy rating on shares of Mesoblast (NASDAQ:MESO) in a research note released on Thursday morning, AnalystRatings.com reports. Maxim Group currently has a $16.00 price objective on the stock.
MESO has been the subject of several other reports. Chardan Capital set a $6.00 price target on Mesoblast and gave the company a hold rating in a report on Friday, August 30th. Zacks Investment Research cut Mesoblast from a buy rating to a hold rating in a report on Friday, September 6th. Oppenheimer set a $10.00 price target on Mesoblast and gave the company a buy rating in a report on Tuesday, September 10th. ValuEngine raised Mesoblast from a hold rating to a buy rating in a report on Tuesday, September 10th. Finally, Cantor Fitzgerald set a $23.00 price target on Mesoblast and gave the company a buy rating in a report on Tuesday, September 10th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Mesoblast presently has a consensus rating of Buy and an average target price of $11.25.
Shares of MESO traded up $0.48 during mid-day trading on Thursday, hitting $7.23. The company’s stock had a trading volume of 111,762 shares, compared to its average volume of 56,423. The company has a current ratio of 1.41, a quick ratio of 1.92 and a debt-to-equity ratio of 0.14. The firm has a 50-day simple moving average of $5.10 and a 200 day simple moving average of $5.10. The firm has a market capitalization of $635.65 million, a P/E ratio of -7.95 and a beta of 1.77. Mesoblast has a 1-year low of $3.35 and a 1-year high of $8.78.
An institutional investor recently raised its position in Mesoblast stock. Morgan Stanley grew its stake in shares of Mesoblast limited (NASDAQ:MESO) by 284.6% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 147,702 shares of the company’s stock after buying an additional 109,295 shares during the period. Morgan Stanley owned 0.16% of Mesoblast worth $784,000 at the end of the most recent reporting period. 2.76% of the stock is currently owned by institutional investors and hedge funds.
Mesoblast Company Profile
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease.
Recommended Story: How prevalent are 12b-1 fees?
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.